Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Objectives
To determine factors associated with COVID-19-related death in people with rheumatic diseases.
Methods
Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category.
Results
Of 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66–75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death.
Conclusion
Among people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants.
Top-30
Journals
|
5
10
15
20
25
30
35
|
|
|
Annals of the Rheumatic Diseases
34 publications, 6.61%
|
|
|
The Lancet Rheumatology
31 publications, 6.03%
|
|
|
Rheumatology
23 publications, 4.47%
|
|
|
RMD Open
17 publications, 3.31%
|
|
|
Clinical Rheumatology
16 publications, 3.11%
|
|
|
Arthritis and Rheumatology
15 publications, 2.92%
|
|
|
International Journal of Rheumatic Diseases
14 publications, 2.72%
|
|
|
Rheumatology International
14 publications, 2.72%
|
|
|
Frontiers in Medicine
11 publications, 2.14%
|
|
|
Frontiers in Immunology
11 publications, 2.14%
|
|
|
Zeitschrift fur Rheumatologie
9 publications, 1.75%
|
|
|
ACR Open Rheumatology
9 publications, 1.75%
|
|
|
Arthritis Care and Research
8 publications, 1.56%
|
|
|
Journal of Clinical Rheumatology
7 publications, 1.36%
|
|
|
Journal of Clinical Medicine
7 publications, 1.36%
|
|
|
Vaccines
6 publications, 1.17%
|
|
|
Joint Bone Spine
6 publications, 1.17%
|
|
|
Seminars in Arthritis and Rheumatism
6 publications, 1.17%
|
|
|
Journal of Rheumatology
6 publications, 1.17%
|
|
|
Current Opinion in Rheumatology
5 publications, 0.97%
|
|
|
Lupus
5 publications, 0.97%
|
|
|
Viruses
5 publications, 0.97%
|
|
|
Advances in Rheumatology
5 publications, 0.97%
|
|
|
Journal of Autoimmunity
5 publications, 0.97%
|
|
|
Modern Rheumatology
5 publications, 0.97%
|
|
|
Therapeutic Advances in Musculoskeletal Disease
4 publications, 0.78%
|
|
|
Vaccine
4 publications, 0.78%
|
|
|
Pathogens
3 publications, 0.58%
|
|
|
Rheumatology and Therapy
3 publications, 0.58%
|
|
|
5
10
15
20
25
30
35
|
Publishers
|
20
40
60
80
100
120
140
|
|
|
Elsevier
138 publications, 26.85%
|
|
|
Springer Nature
86 publications, 16.73%
|
|
|
Wiley
67 publications, 13.04%
|
|
|
MDPI
38 publications, 7.39%
|
|
|
Oxford University Press
37 publications, 7.2%
|
|
|
BMJ
25 publications, 4.86%
|
|
|
Frontiers Media S.A.
24 publications, 4.67%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
17 publications, 3.31%
|
|
|
SAGE
14 publications, 2.72%
|
|
|
Taylor & Francis
13 publications, 2.53%
|
|
|
Cold Spring Harbor Laboratory
7 publications, 1.36%
|
|
|
The Journal of Rheumatology
6 publications, 1.17%
|
|
|
Georg Thieme Verlag KG
4 publications, 0.78%
|
|
|
Termedia Sp. z.o.o.
3 publications, 0.58%
|
|
|
Medknow
3 publications, 0.58%
|
|
|
American College of Physicians
2 publications, 0.39%
|
|
|
Bentham Science Publishers Ltd.
2 publications, 0.39%
|
|
|
Baishideng Publishing Group
2 publications, 0.39%
|
|
|
Hindawi Limited
2 publications, 0.39%
|
|
|
American Society for Microbiology
2 publications, 0.39%
|
|
|
National Library of Serbia
1 publication, 0.19%
|
|
|
Cambridge University Press
1 publication, 0.19%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.19%
|
|
|
eLife Sciences Publications
1 publication, 0.19%
|
|
|
American Society of Clinical Oncology (ASCO)
1 publication, 0.19%
|
|
|
Consilium Medicum
1 publication, 0.19%
|
|
|
Eco-Vector LLC
1 publication, 0.19%
|
|
|
IMA Press, LLC
1 publication, 0.19%
|
|
|
Singapore Medical Association
1 publication, 0.19%
|
|
|
20
40
60
80
100
120
140
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.